Beta-blockers associated with reduced knee osteoarthritis pain: Study

UK: Commonly used beta-blockers may reduce the cumulative risk for knee pain, knee osteoarthritis (OA), and hip pain consultations, finds a recent study in the journal Rheumatology.

Georgina Nakafero, The University of Nottingham, Nottingham, UK, and colleagues aimed to examine the association between β-blocker prescription and first primary-care consultation for knee osteoarthritis, hip OA, knee pain, and hip pain.

The researchers recruited participants from Clinical Practice Research Datalink and included those aged ≥40 years in receipt of new oral β-blocker prescriptions. They were propensity score (PS) matched to an unexposed control. 

Cox proportional hazard ratios (HRs) and 95% confidence intervals (CI) were calculated, and adjusted for non-osteoporotic fractures, number of primary-care consultations for knee or hip injury, and, the number of primary-care consultations, out-patient referrals, and hospitalizations in the 12-months preceding cohort entry. Analysis was stratified according to β-blocker class and for commonly prescribed drugs. 

111 718 β-blocker exposed participants were 1:1 PS matched to unexposed controls. 

"Commonly used β-blockers have analgesic properties for musculoskeletal pain," wrote the authors. "Atenolol might be a therapeutic option for OA and cardiovascular co-morbidities in which β-blockers are indicated, while propranolol may be suitable for people with co-morbid anxiety."

"A confirmatory randomized controlled trial is needed before clinical practice is changed," they concluded. 

Reference:

The study titled, "β-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score matched cohort study," is published in the journal Rheumatology.

DOI: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab234/6169013